Amivantamab Biosimilar - Research Grade

Human

EGFR + MET

>1mg/ml

Human IgG1 (K214R/F405L/K409R)-kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P00533;P08581

Blue ice

This is a research-grade, unconjugated, non-therapeutic recombinant analog of amivantamab, a bispecific antibody that engages the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition factor (MET) simultaneously. It is built as a human IgG1-kappa scaffold whose paired heavy-chain mutations (K214R/F405L/K409R) are characteristic of controlled Fab-arm-exchange bispecific assembly, yielding one anti-EGFR and one anti-MET arm. The reagent reproduces the dual-target binding specificity of the originator so researchers can study EGFR/MET co-engagement, receptor down-modulation, and bispecific-antibody mechanism without a clinical-grade material. It is useful as a binding and specificity control, a benchmarking standard for assay development, a positive control in ADCC/effector-function and receptor-internalization work, and a tool for preclinical in-vitro and in-vivo model characterization. Supplied for research use only in low-endotoxin, bulk milligram-to-gram quantities suitable for repeat experiments and screening campaigns. It is not the clinical drug and is not intended for human or veterinary use. EGFR (P00533, ErbB1/HER1) is a receptor tyrosine kinase whose ligand binding drives dimerization, autophosphorylation, and signaling through RAS-MAPK and PI3K-AKT to promote proliferation and survival; activating mutations and amplification are oncogenic drivers, notably in non-small-cell lung cancer. MET (P08581, the hepatocyte growth factor receptor) is a receptor tyrosine kinase activated by HGF that signals through overlapping RAS-MAPK, PI3K-AKT, and STAT pathways to drive proliferation, motility, and invasion. MET amplification and MET exon-14 skipping are established oncogenic events, and MET activation is a recognized bypass mechanism of resistance to EGFR-targeted therapy. Because the two receptors converge on shared downstream signaling and can compensate for one another, simultaneous EGFR and MET engagement is biologically rational for blocking parallel and bypass signaling and for promoting receptor co-degradation.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, HGF receptor, HGF/SF receptor, Proto-oncogene c-Met, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met, Epidermal growth factor receptor, Hepatocyte growth factor receptor,

Detects EGFRxMET

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.